NEWLAND PHARMACEUTICAL CO., LTD is located in Changge Economic and Technological Development Zone. It is specialized in R&D, production and sales of pharmaceutical intermediates, APIs and formulations.The company is a major global manufacturer of ‌D-p-Hydroxyphenylglycine‌ (the core raw material for producing amoxicillin API) and ‌p-Toluenesulfonic acid‌ (the core raw material for producing doxycycline API). Its products are recognized as patent-intensive products by the China National Intellectual Property Administration. The company has led and participated in the formulation of 4 industry standards for products including D-p-hydroxyphenylglycine, Methyl D-(-)-4-Hydroxyphenylclycinate, p-Toluenesulfonic acid and Glyoxylic Acid, and owns 13 invention patents for key production technologies. Among them, the synthesis technology of D-p-hydroxyphenylglycine has obtained invention authorization from 8 countries including the United States, the United Kingdom, Japan and India. In November 2022, the company's shares were listed on the ChiNext Board of the Shenzhen Stock Exchange (stock abbreviation: Xin Tiandi, stock code: 301277).

       The company has successively won honors such as National Green Factory, National Intellectual Property Advantage Enterprise, High-tech Enterprise, China Quality and Credit Enterprise, Henan Innovation Leading Enterprise, Henan Technology Innovation Demonstration Enterprise, Henan Green Technology Innovation Demonstration Enterprise, and Henan Excellent Private Enterprise (High Growth).

       Focusing on its development strategy for 2025-2030, the company takes "core building & chain strengthening" (core competitiveness, integrated industrial chain) as the main line, and vigorously promotes the strategic planning of "product serialization, technology platform, management digitalization, intelligent innovation, market internationalization, and high-end brand". Relying on two R&D platforms in Beijing and Zhengzhou, the company further gathers advantages of high-end talents and technical achievements in the industry, strengthens and complements the chain around generic drugs and innovative drugs, and accelerates the high-quality development of the biomedical industry.